THE SHARE: Change: -0.01 SEK (-4.53%) / Price: 0.13 SEK / Feb 11, 2026, 5:29 pm (CET)
  • Home
  • About
    • Introduction
    • Board of Directors
    • Management Team
    • Medical Advisors
    • Corporate Governance
    • Career
  • Technology
    • Physiological Targeting
    • Functional Nanoparticles
    • Publications
    • Patent
  • Portfolio
    • Pipeline
    • SpagoPix
    • Tumorad
  • Investor Relations
    • The Share
    • Analyst Coverage
    • Owners
    • Financial Reports
    • Financial Calendar
    • Equity research
    • Shareholder’s Personal Data
    • Share Issue
  • Media
    • Spago Nanomedical in media
    • Press Releases
    • Subscribe
    • Presentations
    • Events
    • Image Bank
  • Contact
    • Contact us

Presentations

CEO Mats Hansen presents at Redeye Theme Event Fight Cancer 2026

21 Jan, 2026

CEO Mats Hansen presents Spago Nanomedical at Life Science Summit 2025

18 Nov, 2025

Encouraged by how the trial is progressing

31 Oct, 2025

Positive development for Tumorad (Swedish)

15 Oct, 2025

DNB Carnegie Småbolagsdag – Spago Nanomedical presentation

3 Sep, 2025

Approaching important results (Swedish)

5 Jun, 2025

Spago on the increased dose in Tumorad-01

4 Apr, 2025

Carnegie Healthcare Seminar 2025 (Swedish)

13 Mar, 2025

Interview with CEO Mats Hansen – Penser by Carnegie (Swedish)

14 Nov, 2024

Interview with CEO Mats Hansen – Västra Hamnen (Swedish)

14 Oct, 2024
Back

About Spago Nanomedical

Spago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of life-threatening and debilitating diseases.

Address

Spago Nanomedical AB
Scheelevägen 22
SE-223 63 Lund
Sweden

Contact

Phone: +46 46 811 88
LinkedIn

Member of:

Copyright © 2026 Spago Nanomedical AB. All Rights Reserved.
Design by Clavis Communications